Log In
BCIQ
Print this Print this
 

LCP-AtorFen

  Manage Alerts
Collapse Summary General Information
Company Veloxis Pharmaceuticals A/S
DescriptionFixed-dose combination of atorvastatin and fenofibrate using MeltDose technology
Molecular Target HMG-CoA reductase ; Peroxisome proliferation activated receptor (PPAR) alpha
Mechanism of ActionHMG-CoA reductase inhibitor; Peroxisome proliferation activated receptor (PPAR) alpha agonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase II
Standard IndicationDyslipidemia
Indication DetailsTreat dyslipidemia
Regulatory Designation
PartnerAthena Pharmaceutiques S.A.S.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/02/2012

0

0

0

Get a free BioCentury trial today